Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Saffron (Crocus sativus stigma extract)

Herbal antidepressant supplement, standardised affron® and Safr'Inside® extracts

ATC code: N06AX-SAFFRON

Brand names – supplements: Saffron 8840 Affron, NOW Saffron Extract, Doctor's Best Saffron, Life Extension Optimized SaffronSupplements are not tested in clinical trials and are not registered as medications.

Updated · Methodology

Indications

C

Mild-to-moderate depression

Adjunct

Saffron is one of the few herbs with a series of meta-analyses in mild to moderate depression. Hausenblas 2013 pooled 5 RCTs with 142 patients, Lopresti 2014 covered 6 RCTs and Marx 2019 covered 11 RCTs. Conclusions converge: saffron is more effective than placebo and comparable to low-dose fluoxetine and imipramine in mild to moderate depression. Effect size is moderate, study duration 6–8 weeks, samples mostly Iranian. No HMPC monograph for saffron exists, and well-established use has not been granted due to limited geography and small sample size. NG222 (2022) does not mention saffron. Standardised affron® and Safr'Inside® extracts at 28–30 mg/day are the only form with reproducible clinical data. In severe depression saffron is not indicated. If saffron is considered as a replacement for standard treatment in moderate or severe depression, consider seeking a second opinion.

Sources

  1. J Integr Med (Hausenblas): Saffron (Crocus sativus L.) and major depressive disorder: a meta-analysis of RCTs (2013)
  2. Hum Psychopharmacol (Lopresti): Saffron (Crocus sativus) for depression: a systematic review of clinical studies (2014)
  3. Neurosci Biobehav Rev (Marx): Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis (2019)
  4. NICE: Depression in adults: treatment and management (NG222) (2022)

ICD-10: F32.0 · ICD-11: 6A70.0

C

Stress and anxiety

Adjunct

Saffron has been studied in mild anxiety symptoms in several RCTs. The Marx 2019 meta-analysis combined trials with anxiety symptoms and showed moderate reduction in anxiety scores vs placebo, with effect size comparable to the antidepressant signal. Certified affron® and Safr'Inside® extracts at 28–30 mg/day over 8 weeks gave a positive signal. No data exist in diagnosed GAD or panic disorder; trials enrolled people with mild anxiety symptoms without a formal diagnosis. CG113 does not mention saffron. For mild episodic anxiety an 8–12-week course is acceptable as an add-on to core measures – CBT, sleep normalisation and physical activity. In diagnosed anxiety disorder replacing standard care with saffron is not justified.

Sources

  1. Neurosci Biobehav Rev (Marx): Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis (2019)
  2. NICE: Generalised anxiety disorder and panic disorder in adults: management (2020)

ICD-10: F41.9 · ICD-11: 6B0Z

Marketing claims without evidence base

The drug is promoted for these uses outside international guidelines. Each entry below is analyzed against AEMPS, FDA, EMA, Cochrane and major RCTs.

D

Longevity and anti-aging biohacking (marketing category)

Not recommended

Saffron is a spice made from the stigmas of the Crocus sativus flower; the extract is marketed as a supplement for longevity and slowing aging. Its benefit for this use has not been proven – there's no solid evidence behind an anti-age effect or any impact on lifespan. Aging responds to other, well-tested things: sun protection, not smoking, sleep, movement and diet.

Sources

  1. USPSTF: Vitamin, mineral and multivitamin supplementation to prevent CVD and cancer (2022)
  2. Neurosci Biobehav Rev (Marx): Effect of saffron supplementation on symptoms of depression and anxiety: a systematic review and meta-analysis (2019)
  3. EFSA: Scientific Opinion on the safety of botanicals used in food supplements (2017)
How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Saffron stigma contains crocin, crocetin, picrocrocin and safranal. Crocin and safranal inhibit serotonin, noradrenaline and dopamine reuptake at the synaptic cleft – the proposed basis for the antidepressant effect reported in small RCTs. Crocetin has antioxidant properties in vitro. Standardised extracts available on the market: affron® (30 mg petals, Pharmactive) and Safr'Inside® (88.5 mg stigma, Activ'Inside) with declared active component content. Standard doses are 28–30 mg of extract per day. No HMPC monograph for saffron exists, no well-established use status granted. Crocin oral bioavailability is low; crocetin is mostly what appears in plasma.

Safety

Contraindications

  • Hypersensitivity to saffron
  • Pregnancy and conception attempts for medicinal doses
  • Bipolar disorder – risk of switch to mania
  • Concurrent use with SSRIs, SNRIs, MAOIs, triptans – serotonin syndrome risk
  • Age under 18

Serious adverse effects

  • Acute toxicity at doses above 5 g/day (vomiting, uterine bleeding, thrombocytopenia)
  • Serotonin syndrome with serotonergic agents
  • Manic episode in patients with unrecognised bipolar disorder

Common adverse effects

  • Nausea
  • Reduced appetite
  • Headache
  • Drowsiness
  • Dry mouth

Pregnancy: can you take Saffron (Crocus sativus stigma extract)?

Saffron in culinary amounts (a few stigma threads in pilaf or dishes) is safe. Medicinal doses of concentrated extracts (28–30 mg/day and above) are contraindicated in pregnancy: historically saffron was used in high doses as an abortifacient, and in animals crocin and safranal at high doses induce uterine contractions and embryotoxicity. AEMPS classifies concentrated saffron products as complementos alimenticios without a pregnancy indication. During pregnancy and conception attempts, medicinal doses of saffron are not taken.

Breastfeeding: can you take Saffron (Crocus sativus stigma extract)?

Data on transfer of crocin and safranal into human milk are lacking. Medicinal doses of saffron during lactation are not justified and not studied in nursing RCTs.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Saffron (Crocus sativus stigma extract) used for?

Saffron (Crocus sativus stigma extract) is evaluated for the following indications with varying evidence strength: Mild-to-moderate depression (evidence tier C), Stress and anxiety (evidence tier C), Longevity and anti-aging biohacking (marketing category) (evidence tier D). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Saffron (Crocus sativus stigma extract)?

Common side effects of Saffron (Crocus sativus stigma extract) (≥ 1 in 100): Nausea, Reduced appetite, Headache, Drowsiness, Dry mouth. See the Safety section for uncommon and serious reactions.

Is Saffron (Crocus sativus stigma extract) safe during pregnancy?

Saffron in culinary amounts (a few stigma threads in pilaf or dishes) is safe. Medicinal doses of concentrated extracts (28–30 mg/day and above) are contraindicated in pregnancy: historically saffron was used in high doses as an abortifacient, and in animals crocin and safranal at high doses induce uterine contractions and embryotoxicity. AEMPS classifies concentrated saffron products as complementos alimenticios without a pregnancy indication. During pregnancy and conception attempts, medicinal doses of saffron are not taken.

Is Saffron (Crocus sativus stigma extract) compatible with breastfeeding?

Data on transfer of crocin and safranal into human milk are lacking. Medicinal doses of saffron during lactation are not justified and not studied in nursing RCTs.

Who should not take Saffron (Crocus sativus stigma extract)?

Saffron (Crocus sativus stigma extract) is contraindicated in: Hypersensitivity to saffron; Pregnancy and conception attempts for medicinal doses; Bipolar disorder – risk of switch to mania; Concurrent use with SSRIs, SNRIs, MAOIs, triptans – serotonin syndrome risk; Age under 18. Full list in the Safety section.

Other drugs in this group

Semax (Met-Glu-His-Phe-Pro-Gly-Pro), Sertraline, Tranylcypromine, Trazodone, 5-hydroxytryptophan (5-HTP), Cortexin (bovine brain cortex polypeptides), Glycine (as a marketed «nootropic»), Noopept (N-phenylacetyl-L-prolylglycine ethyl ester)